Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 2, 2012, Pages 207-222

  Guo, Shanchun ^a   Liu, Mingli ^a   Wang, Guangdi ^b   Torroella Kouri, Marta ^c   Gonzalez Perez, Ruben R ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Breast cancer stem cells; Leptin; Leptin antagonist; Leptin signaling; Tumor angiogenesis

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; GROWTH FACTOR; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEGYLATED LEPTIN PEPTIDE RECEPTOR ANTAGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; STAT PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INCIDENCE; CANCER STEM CELL; CARCINOGENICITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG TARGETING; ENDOCRINE SYSTEM; ENERGY BALANCE; FOOD INTAKE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MITOGENESIS; MOLECULAR INTERACTION; NONHUMAN; OBESITY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; LEPTIN; NEOPLASTIC STEM CELLS; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84862819412     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.01.002     Document Type: Review

References (261)

1. WHO World Health Organization fact sheet for world wide prevalence of obesity http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
2. Baskin M.L., Ard J., Franklin F., Allison D.B. Prevalence of obesity in the United States. Obes. Rev. 2005, 6:5-7.
3. Flegal K.M., Ogden C.L., Carroll M.D. Prevalence and trends in overweight in Mexican-American adults and children. Nutr. Rev. 2004, 62:S144-S148.
4. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
5. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
6. Huxley R., Mendis S., Zheleznyakov E., Reddy S., Chan J. Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk-a review of the literature. Eur. J. Clin. Nutr. 2010, 64:16-22.
7. Travers M.E., McCarthy M.I. Type 2 diabetes and obesity: genomics and the clinic. Hum. Genet. 2011, 130:41-58.
8. Kotsis V., Stabouli S., Papakatsika S., Rizos Z., Parati G. Mechanisms of obesity-induced hypertension. Hypertens. Res. 2010, 33:386-393.
9. Franssen R., Monajemi H., Stroes E.S., Kastelein J.J. Obesity and dyslipidemia. Endocrinol. Metab. Clin. North Am. 2008, 37:623-633. (viii).
10. Cohen J.C., Horton J.D., Hobbs H.H. Human fatty liver disease: old questions and new insights. Science 2011, 332:1519-1523.
11. Basen-Engquist K., Chang M. Obesity and cancer risk: recent review and evidence. Curr. Oncol. Rep. 2011, 13:71-76.
12. Paz-Filho G., Lim E.L., Wong M.L., Licinio J. Associations between adipokines and obesity-related cancer. Front. Biosci. 2011, 16:1634-1650.
13. Teucher B., Rohrmann S., Kaaks R. Obesity: focus on all-cause mortality and cancer. Maturitas 2010, 65:112-116.
14. Wolin K.Y., Carson K., Colditz G.A. Obesity and cancer. Oncologist 2010, 15:556-565.
15. Prieto-Hontoria P.L., Perez-Matute P., Fernandez-Galilea M., Bustos M., Martinez J.A., Moreno-Aliaga M.J. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim. Biophys. Acta 2011, 1807:664-678.
16. Zhang Y., Bellows C.F., Kolonin M.G. Adipose tissue-derived progenitor cells and cancer. World J. Stem Cells 2010, 2:103-113.
17. Kwaan H.C., McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treat. Res. 2009, 148:43-66.
18. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
19. Paracchini V., Pedotti P., Taioli E. Genetics of leptin and obesity: a HuGE review. Am. J. Epidemiol. 2005, 162:101-114.
20. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 2011, 11:886-895.
21. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348:1625-1638.
22. Han C., Zhang H.T., Du L., Liu X., Jing J., Zhao X., Yang X., Tian B. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine 2005, 26:19-24.
23. Wu M.H., Chou Y.C., Chou W.Y., Hsu G.C., Chu C.H., Yu C.P., Yu J.C., Sun C.A. Circulating levels of leptin, adiposity and breast cancer risk. Br. J. Cancer 2009, 100:578-582.
24. Garofalo C., Surmacz E. Leptin and cancer. J. Cell. Physiol. 2006, 207:12-22.
25. Jarde T., Perrier S., Vasson M.P., Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur. J. Cancer 2011, 47:33-43.
26. Ray A., Cleary M.P. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin. Ther. Targets 2010, 14:443-451.
27. Ribeiro R., Lopes C., Medeiros R. Leptin and prostate: implications for cancer prevention-overview of genetics and molecular interactions. Eur. J. Cancer Prev. 2004, 13:359-368.
28. Wang S.N., Lee K.T., Ker C.G. Leptin in hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:5801-5809.
29. Farooqi I.S., Jebb S.A., Langmack G., Lawrence E., Cheetham C.H., Prentice A.M., Hughes I.A., McCamish M.A., O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341:879-884.
30. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B.T., Rabinowitz D., Lallone R.L., Burley S.K., Friedman J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
31. Leinninger G.M. Location, location, location: the CNS sites of leptin action dictate its regulation of homeostatic and hedonic pathways. Int. J. Obes. (Lond) 2009, 33(Suppl 2):S14-S17.
32. Myers M.G., Munzberg H., Leinninger G.M., Leshan R.L. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 2009, 9:117-123.
33. Robertson S.A., Leinninger G.M., Myers M.G. Molecular and neural mediators of leptin action. Physiol. Behav. 2008, 94:637-642.
34. Gonzalez R.R., Leavis P.C. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. Endocrine 2003, 21:185-195.
35. Imagawa K., Numata Y., Katsuura G., Sakaguchi I., Morita A., Kikuoka S., Matumoto Y., Tsuji T., Tamaki M., Sasakura K., Teraoka H., Hosoda K., Ogawa Y., Nakao K. Structure-function studies of human leptin. J. Biol. Chem. 1998, 273:35245-35249.
36. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem. J. 2006, 393:7-20.
37. Friedman J. Leptin, leptin receptors, and the control of body weight. Leptin-the voice of adipose tissue 1997, 3-22. JA Barth Verlag, Heidelberg. W.F. Blum, W. Kiess, W. Rascher (Eds.).
38. Tartaglia L.A., Dembski M., Weng X., Deng N., Culpepper J., Devos R., Richards G.J., Campfield L.A., Clark F.T., Deeds J., Muir C., Sanker S., Moriarty A., Moore K.J., Smutko J.S., Mays G.G., Wool E.A., Monroe C.A., Tepper R.I. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263-1271.
39. Bazan J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6934-6938.
40. Tartaglia L.A. The leptin receptor. J. Biol. Chem. 1997, 272:6093-6096.
41. Banks A.S., Davis S.M., Bates S.H., Myers M.G. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 2000, 275:14563-14572.
42. Bjorbaek C., Uotani S., da Silva B., Flier J.S. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J. Biol. Chem. 1997, 272:32686-32695.
43. Stahl N., Farruggella T.J., Boulton T.G., Zhong Z., Darnell J.E., Yancopoulos G.D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995, 267:1349-1353.
44. Bjorbaek C., El-Haschimi K., Frantz J.D., Flier J.S. The role of SOCS-3 in leptin signaling and leptin resistance. J. Biol. Chem. 1999, 274:30059-30065.
45. Masuzaki H., Ogawa Y., Sagawa N., Hosoda K., Matsumoto T., Mise H., Nishimura H., Yoshimasa Y., Tanaka I., Mori T., Nakao K. Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat. Med. 1997, 3:1029-1033.
46. Smith-Kirwin S.M., O'Connor D.M., De Johnston J., Lancey E.D., Hassink S.G., Funanage V.L. Leptin expression in human mammary epithelial cells and breast milk. J. Clin. Endocrinol. Metab. 1998, 83:1810-1813.
47. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 2002, 94:1704-1711.
48. Jarde T., Caldefie-Chezet F., Damez M., Mishellany F., Perrone D., Penault-Llorca F., Guillot J., Vasson M.P. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 2008, 53:484-487.
49. Schaffler A., Scholmerich J., Buechler C. Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:345-354.
50. Vona-Davis L., Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr. Relat. Cancer 2007, 14:189-206.
51. Yuan S.S., Chung Y.F., Chen H.W., Tsai K.B., Chang H.L., Huang C.H., Su J.H. Aberrant expression and possible involvement of the leptin receptor in bladder cancer. Urology 2004, 63:408-413.
52. Ishikawa M., Kitayama J., Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin. Cancer Res. 2004, 10:4325-4331.
53. Uddin S., Bu R., Ahmed M., Abubaker J., Al-Dayel F., Bavi P., Al-Kuraya K.S. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol. Cancer 2009, 8:74.
54. Hoon Kim J., Lee S.Y., Myung S.C., Kim Y.S., Kim T.H., Kim M.K. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J. Androl. 2008, 10:923-928.
55. Ellerhorst J.A., Diwan A.H., Dang S.M., Uffort D.G., Johnson M.K., Cooke C.P., Grimm E.A. Promotion of melanoma growth by the metabolic hormone leptin. Oncol. Rep. 2010, 23:901-907.
56. Riolfi M., Ferla R., Del Valle L., Pina-Oviedo S., Scolaro L., Micciolo R., Guidi M., Terrasi M., Cetto G.L., Surmacz E. Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol. 2010, 20:481-489.
57. Howard J.M., Beddy P., Ennis D., Keogan M., Pidgeon G.P., Reynolds J.V. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br. J. Surg. 2010, 97:1020-1027.
58. Cheng S.P., Chi C.W., Tzen C.Y., Yang T.L., Lee J.J., Liu T.P., Liu C.L. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010, 147:847-853.
59. Uddin S., Bavi P., Siraj A.K., Ahmed M., Al-Rasheed M., Hussain A.R., Amin T., Alzahrani A., Al-Dayel F., Abubaker J., Bu R., Al-Kuraya K.S. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr. Relat. Cancer 2010, 17:191-202.
60. Kakarala M., Wicha M.S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 2008, 26:2813-2820.
61. Pang L.Y., Argyle D.J. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim. Biophys. Acta 2009, 1792:380-391.
62. Clarke M.F. Self-renewal and solid-tumor stem cells. Biol. Blood Marrow Transplant. 2005, 11:14-16.
63. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
64. Chung A.S., Lee J., Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
65. Savarese T.M., Strohsnitter W.C., Low H.P., Liu Q., Baik I., Okulicz W., Chelmow D.P., Lagiou P., Quesenberry P.J., Noller K.L., Hsieh C.C. Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res. 2007, 9:R29.
66. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
67. Korkaya H., Wicha M.S. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin. Cancer Res. 2009, 15:1845-1847.
68. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
69. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., Margolick J.B., Liotta L.A., Petricoin E., Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16158-16163.
70. Pratt M.A., Tibbo E., Robertson S.J., Jansson D., Hurst K., Perez-Iratxeta C., Lau R., Niu M.Y. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009, 28:2710-2722.
71. Guo S., Gonzalez-Perez R.R. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One 2011, 6(6):e21467.
72. Guo S., Liu M., Gonzalez-Perez R.R. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta 2011, 1815:197-213.
73. Knight B.B., Oprea-Ilies G.M., Nagalingam A., Yang L., Cohen C., Saxena N.K., Sharma D. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin induced migration of breast carcinoma cells. Endocr. Relat. Cancer 2011.
74. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284:770-776.
75. Leong K.G., Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006, 107:2223-2233.
76. Radtke F., Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat. Rev. Cancer 2003, 3:756-767.
77. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
78. Guo S., Gillespie C., Liu M., G.-P.R. Autocrine stimulation of VEGFR-2 by leptin is associated with Notch signaling pathway and cancer stem cell marker expression. AACR 102 Annual Congress, #: 12-A-5965 2012.
79. Zheng Q., Dunlap S.M., Zhu J., Downs-Kelly E., Rich J.N., Hursting S.D., Berger N.A., Reizes O. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth and abrogates tumor initiating cell survival. Endocr. Relat. Cancer 2010, 18(4):491-503.
80. Feldman D.E., Chen C., Punj V., Tsukamoto H., Machida K. Pluripotency factor-mediated expression of the leptin receptor (OB-R) links obesity to oncogenesis through tumor-initiating stem cells. Proc. Natl. Acad. Sci. U. S. A. 2011, (Epub ahead of print) PDMID: 22207628.
81. Berrada N., Delaloge S., Andre F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. Ann. Oncol. 2010, 21(Suppl 7):vii30-vii35.
82. McGlothen T., Gillespie C., Colbert L., Guo S., Gonzalez-Perez R. Leptin signaling impacts on notch and Wnt crosstalk in breast cancer. CTRC-AACR San Antonio Breast Cancer Symposium 2011.
83. Cao R., Brakenhielm E., Wahlestedt C., Thyberg J., Cao Y. Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6390-6395.
84. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., Madge L.A., Schechner J.S., Schwabb M.B., Polverini P.J., Flores-Riveros J.R. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
85. Bouloumie A., Drexler H.C., Lafontan M., Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ. Res. 1998, 83:1059-1066.
86. Paradis H., Gendron R.L. LIF transduces contradictory signals on capillary outgrowth through induction of stat3 and (P41/43)MAP kinase. J. Cell Sci. 2000, 113(Pt 23):4331-4339.
87. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
88. Soldi R., Mitola S., Strasly M., Defilippi P., Tarone G., Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999, 18:882-892.
89. Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta 2010, 1806:108-121.
90. Siclari V.A., Guise T.A., Chirgwin J.M. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 2006, 25:621-633.
91. Gonzalez R.R., Devoto L., Campana A., Bischof P. Effects of leptin, interleukin-1alpha, interleukin-6, and transforming growth factor-beta on markers of trophoblast invasive phenotype: integrins and metalloproteinases. Endocrine 2001, 15:157-164.
92. Gonzalez R.R., Leavis P. Leptin upregulates beta3-integrin expression and interleukin-1beta, upregulates leptin and leptin receptor expression in human endometrial epithelial cell cultures. Endocrine 2001, 16:21-28.
93. Heida N.M., Leifheit-Nestler M., Schroeter M.R., Muller J.P., Cheng I.F., Henkel S., Limbourg A., Limbourg F.P., Alves F., Quigley J.P., Ruggeri Z.M., Hasenfuss G., Konstantinides S., Schafer K. Leptin enhances the potency of circulating angiogenic cells via src kinase and integrin (alpha)vbeta5: implications for angiogenesis in human obesity. Arterioscler. Thromb. Vasc. Biol. 2010, 30:200-206.
94. Schroeter M.R., Leifheit M., Sudholt P., Heida N.M., Dellas C., Rohm I., Alves F., Zientkowska M., Rafail S., Puls M., Hasenfuss G., Konstantinides S., Schafer K. Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ. Res. 2008, 103:536-544.
95. Huang C.Y., Yu H.S., Lai T.Y., Yeh Y.L., Su C.C., Hsu H.H., Tsai F.J., Tsai C.H., Wu H.C., Tang C.H. Leptin increases motility and integrin up-regulation in human prostate cancer cells. J. Cell. Physiol. 2011, 226:1274-1282.
96. Yang S.N., Chen H.T., Tsou H.K., Huang C.Y., Yang W.H., Su C.M., Fong Y.C., Tseng W.P., Tang C.H. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. Carcinogenesis 2009, 30:566-574.
97. Hirai H., Karian P., Kikyo N. Regulation of embryonic stem cell self-renewal and pluripotency by leukaemia inhibitory factor. Biochem. J. 2011, 438:11-23.
98. Ferrara N., Winer J., Henzel W.J. Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:698-702.
99. Vasse M., Pourtau J., Trochon V., Muraine M., Vannier J.P., Lu H., Soria J., Soria C. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1835-1842.
100. Sugiura S., Lahav R., Han J., Kou S.Y., Banner L.R., de Pablo F., Patterson P.H. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur. J. Neurosci. 2000, 12:457-466.
101. Vanderlocht J., Hendriks J.J., Venken K., Stinissen P., Hellings N. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. J. Neuroimmunol. 2006, 177:189-200.
102. Gonzalez R.R., Rueda B.R., Ramos M.P., Littell R.D., Glasser S., Leavis P.C. Leptin-induced increase in leukemia inhibitory factor and its receptor by human endometrium is partially mediated by interleukin 1 receptor signaling. Endocrinology 2004, 145:3850-3857.
103. Carino C., Olawaiye A.B., Cherfils S., Serikawa T., Lynch M.P., Rueda B.R., Gonzalez R.R. Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int. J. Cancer 2008, 123:2782-2790.
104. Dinarello C.A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 1998, 16:457-499.
105. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006, 25:387-408.
106. Perrier S., Caldefie-Chezet F., Vasson M.P. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett. 2009, 583:259-265.
107. Guo S., Fuller M., Gonzalez-Perez R. Regulation of VEGFR-2 by leptin-Notch signaling crosstalk in mammary cancer cells. Abstract #LB-365. 2010.
108. Zhou W., Guo S., Gonzalez-Perez R. Leptin regulates the IL-1 system in breast cancer [abstract]. Abstract nr 1715. 2010.
109. Kumar S., Kishimoto H., Chua H.L., Badve S., Miller K.D., Bigsby R.M., Nakshatri H. Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. Am. J. Pathol. 2003, 163:2531-2541.
110. Ljung L., Olsson T., Engstrand S., Wallberg-Jonsson S., Soderberg S., Rantapaa-Dahlqvist S. Interleukin-1 receptor antagonist is associated with both lipid metabolism and inflammation in rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25:617-620.
111. Reichlin S., Chen G., Nicolson M. Blood to brain transfer of leptin in normal and interleukin-1beta-treated male rats. Endocrinology 2000, 141:1951-1954.
112. Ueland T., Kristo C., Godang K., Aukrust P., Bollerslev J. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. J. Clin. Endocrinol. Metab. 2003, 88:1492-1496.
113. Zhou W., Guo S., Gonzalez-Perez R.R. Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling. Br. J. Cancer 2011, 104:128-137.
114. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 1999, 237:1-30.
115. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
116. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 2006, 312:549-560.
117. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., Sullivan B.T., Sakamoto H., Olawaiye A., Serikawa T., Lynch M.P., Rueda B.R. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem. 2006, 281:26320-26328.
118. Rene Gonzalez R., Watters A., Xu Y., Singh U.P., Mann D.R., Rueda B.R., Penichet M.L. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11:R36.
119. Gonzalez-Perez R.R., Xu Y., Guo S., Watters A., Zhou W., Leibovich S.J. Leptin upregulates VEGF in breast cancer via canonic and non-canonical signalling pathways and NFkappaB/HIF-1alpha activation. Cell. Signal. 2010, 22:1350-1362.
120. Garonna E., Botham K.M., Birdsey G.M., Randi A.M., Gonzalez-Perez R.R., Wheeler-Jones C.P. Vascular endothelial growth factor receptor-2 couples cyclo-oxygenase-2 with pro-angiogenic actions of leptin on human endothelial cells. PLoS One 2011, 6:e18823.
121. Aesoy R., Sanchez B.C., Norum J.H., Lewensohn R., Viktorsson K., Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 2008, 6:1630-1638.
122. Beecken W.D., Kramer W., Jonas D. New molecular mediators in tumor angiogenesis. J. Cell. Mol. Med. 2000, 4:262-269.
123. Cirillo D., Rachiglio A.M., la Montagna R., Giordano A., Normanno N. Leptin signaling in breast cancer: an overview. J. Cell. Biochem. 2008, 105:956-964.
124. Hausman G.J., Richardson R.L. Adipose tissue angiogenesis. J. Anim. Sci. 2004, 82:925-934.
125. Ando S., Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat. Rev. Endocrinol. 2011, (Epub ahead of print). 10.1038/nrendo.2011.184.
126. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
127. Pahler J.C., Tazzyman S., Erez N., Chen Y.Y., Murdoch C., Nozawa H., Lewis C.E., Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
128. Lambert K.C., Curran E.M., Judy B.M., Milligan G.N., Lubahn D.B., Estes D.M. Estrogen receptor alpha (ERalpha) deficiency in macrophages results in increased stimulation of CD4+ T cells while 17beta-estradiol acts through ERalpha to increase IL-4 and GATA-3 expression in CD4+ T cells independent of antigen presentation. J. Immunol. 2005, 175:5716-5723.
129. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., Klein A.S., Bulkley G.B., Bao C., Noble P.W., Lane M.D., Diehl A.M. Leptin regulates proinflammatory immune responses. FASEB J. 1998, 12:57-65.
130. Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 2007, 117:175-184.
131. Lumeng C.N., Deyoung S.M., Bodzin J.L., Saltiel A.R. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
132. Blanco A.M., Valles S.L., Pascual M., Guerri C. Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. J. Immunol. 2005, 175:6893-6899.
133. Zhong S., Ye W.P., Xu P.P., Feng E., Li H., Lin S.H., Liu J.Y., Ma C., Lin Y.C. Aromatase expression in leptin-pretreated human breast pre-adipocytes is enhanced by zeranol and suppressed by (-)-gossypol. Anticancer Res. 2010, 30:5077-5084.
134. Koda M., Sulkowska M., Kanczuga-Koda L., Jarzabek K., Sulkowski S. Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem. Cytobiol. 2007, 45(Suppl 1):S187-S191.
135. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
136. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., Zhang S., Wang T., Sinibaldi D., Coppola D., Heller R., Ellis L.M., Karras J., Bromberg J., Pardoll D., Jove R., Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21:2000-2008.
137. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., Hu X.B., Zheng M.H., Liang L., Feng L., Liang Y.M., Han H. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010, 70:4840-4849.
138. Kaler P., Augenlicht L., Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 2009, 28:3892-3902.
139. Jinushi M., Chiba S., Yoshiyama H., Masutomi K., Kinoshita I., Dosaka-Akita H., Yagita H., Takaoka A., Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12425-12430.
140. Jing Y., Han Z., Zhang S., Liu Y., Wei L. Epithelial-Mesenchymal Transition in tumor microenvironment. Cell Biosci. 2011, 1:29.
141. Pischon T., Nothlings U., Boeing H. Obesity and cancer. Proc. Nutr. Soc. 2008, 67:128-145.
142. Akther A., Khan K.H., Begum M., Parveen S., Kaiser M.S., Chowdhury A.Z. Leptin: a mysterious hormone; its physiology and pathophysiology. Mymensingh Med. J. 2009, 18:S140-S144.
143. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., Kahn B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
144. Myers M.G., Cowley M.A., Munzberg H. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 2008, 70:537-556.
145. Boras-Granic K., Wysolmerski J.J. Wnt signaling in breast organogenesis. Organogenesis 2008, 4:116-122.
146. Prosperi J.R., Goss K.H. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer. Curr. Drug Targets 2010, 11:1074-1088.
147. Fenton J.I., Lavigne J.A., Perkins S.N., Liu H., Chandramouli G.V., Shih J.H., Hord N.G., Hursting S.D. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an Apc genotype-dependent fashion. Mol. Carcinog. 2008, 47:9-21.
148. Endo H., Hosono K., Uchiyama T., Sakai E., Sugiyama M., Takahashi H., Nakajima N., Wada K., Takeda K., Nakagama H., Nakajima A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60(10):1363-1371.
149. Gillespie C., Colbert L., McGlothen T., Guo S., Zhou W., Gonzalez-Perez R.R. DMBA-Breast Cancer in Diet Induced Obesity (DIO) and Lean Mice is related to Leptin Signaling CTRC-AACR San Antonio Breast Cancer Symposium 2011.
150. Kovall R.A. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene 2008, 27:5099-5109.
151. Danovi S.A. Angiogenesis: turning it down a notch. Nat. Rev. Cancer 2008, 8:572-573.
152. Polus A G.J., Piatkowska E., Dembinska-Kiec A. Differences in leptin, VEGF, and bFGF-induced angiogenic differentiation of HUVEC and human umbilical blood CD34+ progenitor cells. European Journal of Biochemistry 2003, Abstract number: P4.1-67.
153. Lanier V., Gillespie C., McGlothen T., Dickson T., Guo S., Gonzalez-Perez R.R. Leptin induces Notch in endothelial cells: role of VEGFR-2 transactivation. AACR 102 Annual Congress 2012.
154. Tai W., Mahato R., Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 2010, 146(3):264-275.
155. Tzahar E., Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim. Biophys. Acta 1998, 1377:M25-M37.
156. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
157. Ray A., Nkhata K.J., Cleary M.P. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int. J. Oncol. 2007, 30:1499-1509.
158. Soma D., Kitayama J., Yamashita H., Miyato H., Ishikawa M., Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J. Surg. Res. 2008, 149:9-14.
159. Fiorio E., Mercanti A., Terrasi M., Micciolo R., Remo A., Auriemma A., Molino A., Parolin V., Di Stefano B., Bonetti F., Giordano A., Cetto G.L., Surmacz E. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305.
160. Jernstrom H., Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J. Womens Health Gend. Based Med. 1999, 8:1265-1272.
161. Campfield L.A., Smith F.J., Guisez Y., Devos R., Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995, 269:546-549.
162. Irwin M.L., McTiernan A., Bernstein L., Gilliland F.D., Baumgartner R., Baumgartner K., Ballard-Barbash R. Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2881-2888.
163. Johansson H., Gandini S., Guerrieri-Gonzaga A., Iodice S., Ruscica M., Bonanni B., Gulisano M., Magni P., Formelli F., Decensi A. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res. 2008, 68:9512-9518.
164. Fischer S., Hanefeld M., Haffner S.M., Fusch C., Schwanebeck U., Kohler C., Fucker K., Julius U. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002, 39:105-110.
165. Matsubara M., Maruoka S., Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur. J. Endocrinol. 2002, 147:173-180.
166. Renehan A.G., Harvie M., Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr. Relat. Cancer 2006, 13:273-278.
167. Garofalo C., Koda M., Cascio S., Sulkowska M., Kanczuga-Koda L., Golaszewska J., Russo A., Sulkowski S., Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin. Cancer Res. 2006, 12:1447-1453.
168. Ozbay T., Nahta R. A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells. Mol. Cancer Res. 2008, 6:1052-1058.
169. Saxena N.K., Taliaferro-Smith L., Knight B.B., Merlin D., Anania F.A., O'Regan R.M., Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008, 68:9712-9722.
170. Garofalo C., Sisci D., Surmacz E. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells. Clin. Cancer Res. 2004, 10:6466-6475.
171. Surmacz E. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5:95-105.
172. Steelman L.S., Stadelman K.M., Chappell W.H., Horn S., Basecke J., Cervello M., Nicoletti F., Libra M., Stivala F., Martelli A.M., McCubrey J.A. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 2008, 12:1139-1165.
173. Wickenden J.A., Watson C.J. Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res. 2010, 12:202.
174. Sabbah M., Emami S., Redeuilh G., Julien S., Prevost G., Zimber A., Ouelaa R., Bracke M., De Wever O., Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11:123-151.
175. Dillon R.L., Muller W.J. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res. 2010, 70:4260-4264.
176. Cheng S.P., Yin P.H., Hsu Y.C., Chang Y.C., Huang S.Y., Lee J.J., Chi C.W. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol. Rep. 2011, 26:1265-1271.
177. Uddin S., Bu R., Ahmed M., Hussain A.R., Ajarim D., Al-Dayel F., Bavi P., Al-kuraya K.S. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leuk. Lymphoma 2010, 51:1305-1314.
178. Uddin S., Bavi P.P., Hussain A.R., Alsbeih G., Al-Sanea N., Abduljabbar A., Ashari L.H., Alhomoud S., Al-Dayel F., Ahmed M., Al-Kuraya K.S. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis 2009, 30:1832-1840.
179. Shen Y., Wang Q., Zhao Q., Zhou J. Leptin promotes the immune escape of lung cancer by inducing proinflammatory cytokines and resistance to apoptosis. Mol. Med. Rep. 2009, 2:295-299.
180. Gao J., Tian J., Lv Y., Shi F., Kong F., Shi H., Zhao L. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009, 100:389-395.
181. Miyazaki T., Bub J.D., Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim. Biophys. Acta 2008, 1782:593-604.
182. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
183. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl 2):S43-S51.
184. Russell R.C., Fang C., Guan K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138:3343-3356.
185. Ciuffreda L., Di Sanza C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 2010, 10:484-495.
186. Jung C.H., Ro S.H., Cao J., Otto N.M., Kim D.H. mTOR regulation of autophagy. FEBS Lett. 2010, 584:1287-1295.
187. Attoub S., Noe V., Pirola L., Bruyneel E., Chastre E., Mareel M., Wymann M.P., Gespach C. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J. 2000, 14:2329-2338.
188. Maya-Monteiro C.M., Bozza P.T. Leptin and mTOR: partners in metabolism and inflammation. Cell Cycle 2008, 7:1713-1717.
189. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.
190. Ghayad S.E., Cohen P.A. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients. Recent Pat. Anticancer Drug Discov. 2010, 5:29-57.
191. Hadad S.M., Fleming S., Thompson A.M. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit. Rev. Oncol. Hematol. 2008, 67:1-7.
192. Noh W.C., Kim Y.H., Kim M.S., Koh J.S., Kim H.A., Moon N.M., Paik N.S. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat. 2008, 110:477-483.
193. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
194. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 2010, 336:25-37.
195. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
196. Takada Y., Ichikawa H., Badmaev V., Aggarwal B.B. Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression. J. Immunol. 2006, 176:3127-3140.
197. Sethi G., Ahn K.S., Sandur S.K., Lin X., Chaturvedi M.M., Aggarwal B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J. Biol. Chem. 2006, 281:23425-23435.
198. Mattace Raso G., Esposito E., Iacono A., Pacilio M., Coppola A., Bianco G., Diano S., Di Carlo R., Meli R. Leptin induces nitric oxide synthase type II in C6 glioma cells. Role for nuclear factor-kappaB in hormone effect. Neurosci. Lett. 2006, 396:121-126.
199. Yeh W.L., Lu D.Y., Lee M.J., Fu W.M. Leptin induces migration and invasion of glioma cells through MMP-13 production. Glia 2009, 57:454-464.
200. Ogunwobi O.O., Beales I.L. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig. Dis. Sci. 2007, 52:1934-1945.
201. Rouet-Benzineb P., Aparicio T., Guilmeau S., Pouzet C., Descatoire V., Buyse M., Bado A. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J. Biol. Chem. 2004, 279:16495-16502.
202. Fletcher S., Drewry J.A., Shahani V.M., Page B.D., Gunning P.T. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 2009, 87:825-833.
203. Masciocchi D., Gelain A., Villa S., Meneghetti F., Barlocco D. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy. Future Med. Chem. 2011, 3:567-597.
204. Mankan A.K., Greten F.R. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin. Investig. Drugs 2011, 20:1263-1275.
205. Zhao M., Jiang B., Gao F.H. Small molecule inhibitors of STAT3 for cancer therapy. Curr. Med. Chem. 2011, 18(26):4012-4018.
206. Bates S.H., Kulkarni R.N., Seifert M., Myers M.G. Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis. Cell Metab. 2005, 1:169-178.
207. Ratke J., Entschladen F., Niggemann B., Zanker K.S., Lang K. Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways. Endocr. Relat. Cancer 2010, 17:179-189.
208. Catalano S., Giordano C., Rizza P., Gu G., Barone I., Bonofiglio D., Giordano F., Malivindi R., Gaccione D., Lanzino M., De Amicis F., Ando S. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J. Cell. Physiol. 2009, 218:490-500.
209. Li L., Gao Y., Zhang L.L., He D.L. Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol. Ther. 2008, 7:1787-1792.
210. Saxena N.K., Vertino P.M., Anania F.A., Sharma D. leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J. Biol. Chem. 2007, 282:13316-13325.
211. Pai R., Lin C., Tran T., Tarnawski A. Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation. Biochem. Biophys. Res. Commun. 2005, 331:984-992.
212. Yin N., Wang D., Zhang H., Yi X., Sun X., Shi B., Wu H., Wu G., Wang X., Shang Y. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004, 64:5870-5875.
213. Dieudonne M.N., Machinal-Quelin F., Serazin-Leroy V., Leneveu M.C., Pecquery R., Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 2002, 293:622-628.
214. Ogunwobi O.O., Beales I.L. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int. J. Colorectal Dis. 2007, 22:401-409.
215. Russo V.C., Metaxas S., Kobayashi K., Harris M., Werther G.A. Antiapoptotic effects of leptin in human neuroblastoma cells. Endocrinology 2004, 145:4103-4112.
216. Cascio S., Ferla R., D'Andrea A., Gerbino A., Bazan V., Surmacz E., Russo A. Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. J. Cell. Physiol. 2009, 221:189-194.
217. Ren H., Zhao T., Wang X., Gao C., Wang J., Yu M., Hao J. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2010, 394:59-63.
218. Jiang H., Yu J., Guo H., Song H., Chen S. Upregulation of survivin by leptin/STAT3 signaling in MCF-7 cells. Biochem. Biophys. Res. Commun. 2008, 368:1-5.
219. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
220. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 2006, 59:15-26.
221. Li Y., Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. Curr. Cancer Drug Targets 2010, 10(7):782-796.
222. Li Z., Rich J.N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 2010, 345:21-30.
223. Grosfeld A., Andre J., Hauguel-De Mouzon S., Berra E., Pouyssegur J., Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J. Biol. Chem. 2002, 277:42953-42957.
224. Wu M.H., Chen K.F., Lin S.C., Lgu C.W., Tsai S.J. Aberrant expression of leptin in human endometriotic stromal cells is induced by elevated levels of hypoxia inducible factor-1alpha. Am. J. Pathol. 2007, 170:590-598.
225. Koda M., Sulkowska M., Wincewicz A., Kanczuga-Koda L., Musiatowicz B., Szymanska M., Sulkowski S. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann. N. Y. Acad. Sci. 2007, 1095:90-98.
226. Koda M., Sulkowska M., Kanczuga-Koda L., Cascio S., Colucci G., Russo A., Surmacz E., Sulkowski S. Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1 alpha in human colorectal cancer. Ann. Oncol. 2007, 18(Suppl 6):vi116-vi119.
227. Cascio S., Bartella V., Auriemma A., Johannes G.J., Russo A., Giordano A., Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 2008, 27:540-547.
228. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001, 344:276-285.
229. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988, 48:246-253.
230. Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 1993, 15:48-65.
231. Johnston S.R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16:1979-1987.
232. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340:1801-1811.
233. Welboren W.J., Stunnenberg H.G., Sweep F.C., Span P.N. Identifying estrogen receptor target genes. Mol. Oncol. 2007, 1:138-143.
234. Henson M.C., Castracane V.D. Leptin: roles and regulation in primate pregnancy. Semin. Reprod. Med. 2002, 20:113-122.
235. Jarde T., Caldefie-Chezet F., Damez M., Mishellany F., Penault-Llorca F., Guillot J., Vasson M.P. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol. Rep. 2008, 19:905-911.
236. Marttunen M.B., Andersson S., Hietanen P., Karonen S.L., Koistinen H.A., Koivisto V.A., Tiitinen A., Ylikorkala O. Antiestrogenic tamoxifen and toremifene increase serum leptin levels in postmenopausal breast cancer patients. Maturitas 2000, 35:175-179.
237. Catalano S., Mauro L., Marsico S., Giordano C., Rizza P., Rago V., Montanaro D., Maggiolini M., Panno M.L., Ando S. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J. Biol. Chem. 2004, 279:19908-19915.
238. Catalano S., Marsico S., Giordano C., Mauro L., Rizza P., Panno M.L., Ando S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 2003, 278:28668-28676.
239. Altieri D.C. New wirings in the survivin networks. Oncogene 2008, 27:6276-6284.
240. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
241. Abdraboh M.E., Gaur R.L., Hollenbach A.D., Sandquist D., Raj M.H., Ouhtit A. Survivin is a novel target of CD44-promoted breast tumor invasion. Am. J. Pathol. 2011, 179:555-563.
242. Bray S.J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 2006, 7:678-689.
243. Lee C.W., Raskett C.M., Prudovsky I., Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68:5273-5281.
244. Lee C.W., Simin K., Liu Q., Plescia J., Guha M., Khan A., Hsieh C.C., Altieri D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 2008, 10:R97.
245. Perera C.N., Chin H.G., Duru N., Camarillo I.G. Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. J. Endocrinol. 2008, 199:221-233.
246. Rose D.P., Komninou D., Stephenson G.D. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes. Rev. 2004, 5:153-165.
247. Bartella V., Cascio S., Fiorio E., Auriemma A., Russo A., Surmacz E. Insulin-dependent leptin expression in breast cancer cells. Cancer Res. 2008, 68:4919-4927.
248. Fasshauer M., Klein J., Neumann S., Eszlinger M., Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2002, 290:1084-1089.
249. Miyoshi Y., Funahashi T., Kihara S., Taguchi T., Tamaki Y., Matsuzawa Y., Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin. Cancer Res. 2003, 9:5699-5704.
250. Jarde T., Caldefie-Chezet F., Goncalves-Mendes N., Mishellany F., Buechler C., Penault-Llorca F., Vasson M.P. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr. Relat. Cancer 2009, 16:1197-1210.
251. Revillion F., Charlier M., Lhotellier V., Hornez L., Giard S., Baranzelli M.C., Djiane J., Peyrat J.P. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin. Cancer Res. 2006, 12:2088-2094.
252. Kim H.S. Leptin and leptin receptor expression in breast cancer. Cancer Res. Treat. 2009, 41:155-163.
253. Otvos L., Kovalszky I., Riolfi M., Ferla R., Olah J., Sztodola A., Nama K., Molino A., Piubello Q., Wade J.D., Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur. J. Cancer 2011, 47:1578-1584.
254. Gillespie C., Guo S., Zhou W., Gonzalez-Perez R.R. Leptin signaling disruption prevents DMBA-induced mammary tumors in lean and diet-induced-obesity (DIO) mice. AACR 102 Annual Congress, Abstract 825 2011.
255. Aloulou N., Bastuji-Garin S., Le Gouvello S., Abolhassani M., Chaumette M.T., Charachon A., Leroy K., Sobhani I. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res. 2008, 68:9413-9422.
256. Paik S.S., Jang S.M., Jang K.S., Lee K.H., Choi D., Jang S.J. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann. Surg. Oncol. 2009, 16:297-303.
257. Wincewicz A., Koda M., Sulkowska M., Kanczuga-Koda L., Sulkowski S. Comparison of STAT3 with HIF-1alpha, Ob and ObR expressions in human endometrioid adenocarcinomas. Tissue Cell 2008, 40:405-410.
258. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Zheng R., Nanus D.M., Hayakawa M. Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J. Urol. 2006, 176:1631-1635.
259. Wang S.N., Chuang S.C., Yeh Y.T., Yang S.F., Chai C.Y., Chen W.T., Kuo K.K., Chen J.S., Lee K.T. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J. Clin. Pathol. 2006, 59:1267-1271.
260. Wang S.N., Yeh Y.T., Yang S.F., Chai C.Y., Lee K.T. Potential role of leptin expression in hepatocellular carcinoma. J. Clin. Pathol. 2006, 59:930-934.
261. Zhang Y.B., Fang M., He F.L., Hua T.F., Hu B.D., Zhao H., Liu R.Y. Mechanism of regulation of leptin expression in human lung adenocarcinoma cells by hypoxia inducible factor-1alpha: a preliminary study. Zhonghua Yi Xue Za Zhi 2008, 88:2848-2853.